Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2024-07-02 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
Share Issue/Capital Change Classification · 100% confidence The document is a detailed monthly report on movements in securities, specifically focusing on authorized/registered share capital, issued shares, treasury shares, share options, and other related share capital changes for Ascletis Pharma Inc. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content is structured as a regulatory submission detailing share capital and share movements for the month ended 30 June 2024. There is no indication of financial performance data, earnings, management discussion, or audit information. The document is not an announcement of a report but a regulatory filing itself. Given the nature of the content—movements in share capital and share options—it fits best under the category of Share Issue/Capital Change (SHA).
2024-07-02 English
VOLUNTARY ANNOUNCEMENT - PROPOSED SHARE REPURCHASE UNDER THE REPURCHASE MANDATE
Transaction in Own Shares Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding a proposed share repurchase under an existing repurchase mandate approved at the AGM. It discusses the intention to repurchase shares on the open market, the financial rationale, funding source, compliance with listing rules, and conditions for the repurchase. The document is relatively short (4290 characters) and serves as an announcement of a capital action rather than a detailed financial report or actual transaction report. It does not contain financial statements or detailed analysis but rather informs shareholders and the market about the company's plan to repurchase shares. This fits the definition of a Transaction in Own Shares (POS) filing, which covers announcements of share repurchase plans or activities.
2024-07-02 English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 13 JUNE 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement from World Houseware (Holdings) Limited regarding the poll results of an Extraordinary General Meeting (EGM) held on 13 June 2024. It details the voting outcome on the adoption of a Share Option Scheme, including vote counts and percentages. The document does not contain financial statements or detailed financial analysis but reports the official voting results of a shareholder meeting. The length is 3758 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-06-13 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 13 JUNE 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the poll results from the Annual General Meeting (AGM) held on 13 June 2024. It details the voting outcomes on various resolutions including adoption of audited financial statements, re-election of directors, re-appointment of auditors, and granting of mandates to directors. The document is relatively short (4561 characters) and serves to officially communicate the voting results rather than presenting the full AGM materials or the annual report itself. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'.
2024-06-13 English
VOLUNTARY ANNOUNCEMENT - GANNEX ANNOUNCES POSTER PRESENTATION DESCRIBING POSITIVE INTERIM 12-WEEK RESULTS FROM ONGOING 52-WEEK PHASE II CLINICAL TRIAL OF ONCE-DAILY ASC41 IN PATIENTS WITH BIOPSY-CONFI
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding a poster presentation of positive interim 12-week results from an ongoing 52-week Phase II clinical trial of ASC41. It includes detailed clinical trial data, safety data, and background on the drug and trial design. The document is not a full financial report, earnings release, or regulatory filing. It is a business development update focused on clinical trial progress and results, not related to financial performance or governance. It is also not a report publication announcement since it contains substantive data and analysis rather than just announcing a report's availability. The content fits best under a general regulatory announcement category for business updates that do not fit other specific financial or governance categories. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-06-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 May 2024. It details movements in authorized/registered share capital, issued shares, share options, and confirms no changes in warrants or convertibles. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share issuance movements for a specific month. It is not a financial report, earnings release, or management discussion. It is a regulatory filing reporting share capital movements and share option details as required by exchange rules. The document length is about 5800 characters, and it is a formal regulatory return rather than a report or announcement of a report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-06-04 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.